Search

Displaying results 5681 - 5690 of 10000 in total
  1. Drug

    CX-046684

    go.drugbank.com/drugs/DB19414
    Approved

    It is the active ingredient of the 2024-2025 formulation of Moderna's Spikevax vaccine.[L40074] … CX-046684 is a COVID-19 mRNA vaccine encoding the pre-fusion stabilized Spike glycoprotein (S) of the SARS-CoV-2 Omicron variant lineage KP.2.

  2. Drug

    Lexanersen

    go.drugbank.com/drugs/DB17933
    Investigational

    Lexanersen is an antisense oligonucleotide under investigation for use as a disease-modifying therapy in Huntington's disease.

  3. Drug

    MaaT013

    go.drugbank.com/drugs/DB18648
    Investigational

    MaaT013 is an allogeneic fecal microbiota therapy. It is being investigated for the treatment of Graft-Versus-Host Disease.

  4. Target

    Integrin alpha-X

    go.drugbank.com/bio_entities/BE0009967
    TargetHumans

    Functions as a receptor of the erythrocyte-specific adhesion molecule ICAM4 and mediates erythrophagocytosis (PubMed:16985175) … Integrin alpha-X/beta-2 is a receptor for fibrinogen. It recognizes the sequence G-P-R in fibrinogen. It mediates cell-cell interaction during inflammatory responses.

    Synonyms: Leukocyte adhesion receptor p150,95
  5. Drug

    Pegpleranib

    go.drugbank.com/drugs/DB06325
    Investigational

  6. Drug

    WIN 55212-2

    go.drugbank.com/drugs/DB13950
    Experimental

    It is a potent cannabinoid receptor agonist that has been found to be a potent analgesic in a rat model of neuropathic pain. It activates p42 and p44 MAP kinase via receptor-mediated signaling. … WIN 55,212-2 is a chemical described as an aminoalkylindole derivative, which produces effects similar to those of cannabinoids such as tetrahydrocannabinol (THC) but has an entirely different chemical

    Categories: Cannabinoid Receptor Antagonists, Receptor, Cannabinoid, CB1, antagonists & inhibitors
  7. Drug

    Mupadolimab

    go.drugbank.com/drugs/DB16488
    Investigational

    CPI-006 was investigated in clinical trials NCT03454451, NCT04464395, and NCT04734873 to evaluate its safety and efficacy.

  8. Drug

    IDD-1

    go.drugbank.com/drugs/DB05439
    Experimental

    Eladem (IDD-1) is a therapeutic vaccine consisting of dendritophages that are loaded in vitro with tumor antigens and then reinjected into the subject. … As with other monoclonal antibodies, this process stimulates an immune response to a particular disease-related antigen.

  9. Drug

    Brolucizumab

    go.drugbank.com/drugs/DB14864
    ApprovedInvestigational

    [L9089] Brolucizumab was granted FDA approval in October 2019.[L9089] … Brolucizumab, also known as RTH258 or ESBA1008,[A187211] is a monoclonal antibody indicated to treat neovascular age related macular degeneration.

  10. Drug

    Drotrecogin alfa

    go.drugbank.com/drugs/DB00055
    ApprovedWithdrawn

    Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. … Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective in improving outcomes in patients with sepsis.